Characterization and Targeting of Leukemia Stem Cells in Human Hematologic Malignancies

The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). The lab is also interested in developing a similar characterization of normal human hematopoiesis and hematopoietic stem cells. A major focus is the identification of cell surface molecules preferentially expressed on leukemia stem cells and the development of therapeutic monoclonal antibodies targeting these proteins. Toward this goal, together with Irv Weissman, the lab is actively developing an anti-CD47 antibody for clinical trials in human AML.